These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35426754)

  • 1. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.
    Rossi GN; Hallak JEC; Bouso Saiz JC; Dos Santos RG
    Expert Opin Drug Saf; 2022 Jun; 21(6):761-776. PubMed ID: 35426754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
    Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI
    J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats.
    Malikowska-Racia N; Koniewski M; Golebiowska J; Popik P
    J Psychopharmacol; 2023 Nov; 37(11):1149-1156. PubMed ID: 37842884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
    Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL
    Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability.
    Rossi GN; Dias ICDS; Baker G; Bouso Saiz JC; Dursun SM; Hallak JEC; Dos Santos RG
    Expert Opin Drug Saf; 2022 Jun; 21(6):789-801. PubMed ID: 35301934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
    Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects.
    Abramson HA; Rolo A
    J Asthma Res; 1965 Sep; 3(1):81-96. PubMed ID: 5318626
    [No Abstract]   [Full Text] [Related]  

  • 10. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
    Dos Santos RG; Hallak JE; Baker G; Dursun S
    J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.
    Müller F; Kraus E; Holze F; Becker A; Ley L; Schmid Y; Vizeli P; Liechti ME; Borgwardt S
    Psychopharmacology (Berl); 2022 Jun; 239(6):1933-1943. PubMed ID: 35076721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic potential of psilocybin: a systematic review.
    van Amsterdam J; van den Brink W
    Expert Opin Drug Saf; 2022 Jun; 21(6):833-840. PubMed ID: 35225143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.
    Hibicke M; Landry AN; Kramer HM; Talman ZK; Nichols CD
    ACS Chem Neurosci; 2020 Mar; 11(6):864-871. PubMed ID: 32133835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.
    Dos Santos RG; Osório FL; Crippa JA; Riba J; Zuardi AW; Hallak JE
    Ther Adv Psychopharmacol; 2016 Jun; 6(3):193-213. PubMed ID: 27354908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study.
    Family N; Hendricks PS; Williams LT; Luke D; Krediet E; Maillet EL; Raz S
    J Psychopharmacol; 2022 Mar; 36(3):321-336. PubMed ID: 35253516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?
    Whelan A; Johnson MI
    Pain Manag; 2018 May; 8(3):217-229. PubMed ID: 29722608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are psychedelics the answer to chronic pain: A review of current literature.
    Kooijman NI; Willegers T; Reuser A; Mulleners WM; Kramers C; Vissers KCP; van der Wal SEI
    Pain Pract; 2023 Apr; 23(4):447-458. PubMed ID: 36597700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential use of psilocybin drugs in the treatment of depression.
    Śladowska K; Kawalec P; Brzostek T; Pilc A
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):241-256. PubMed ID: 37817501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
    Leger RF; Unterwald EM
    J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.